Beyond Ketosis: Dietary Therapies and the Microbiota-Gut-Brain Axis in Epilepsy
الحميات الغذائية والمحور الأمعاء-المخ في الصرع
Journal: Nutrients
University: institution
Study Type: review
Evidence Level: low
Published:
30-Second Summary
This narrative review examines how dietary therapies for epilepsy may influence the microbiota-gut-brain axis beyond ketosis, drawing on clinical and experimental evidence. It discusses how changes in gut microbiota, intestinal barrier integrity, and immune signaling may mediate effects on neuronal excitability and treatment responsiveness, with a focus on ketogenic diets, MAD, LGIT, and related dietary patterns.
1-Minute Summary
This narrative review synthesizes clinical and experimental evidence on the link between epilepsy, gut microbiota, and dietary therapies. It describes how ketosis-based diets and other dietary patterns may alter gut microbial ecology, intestinal barrier integrity, and immune signaling, potentially modulating neuroinflammation and neuronal excitability via the MGBA. It covers ketogenic diets, Modified Atkins Diet, LGIT, and Mediterranean-style patterns, highlighting mechanistic pathways and gaps in the current literature. The review emphasizes the need for more systematic studies to clarify causal relationships and therapeutic implications.
3-Minute Summary
This narrative review synthesizes clinical and experimental evidence on the microbiota-gut-brain axis (MGBA) as a mediator of epilepsy and dietary therapies. Beyond ketosis, dietary interventions such as the ketogenic diet (KD), Modified Atkins Diet (MAD), low-glycemic-index treatment (LGIT), and Mediterranean-style patterns may influence seizure biology by reshaping the gut microbiota, improving intestinal barrier integrity, and modulating immune signaling. The review notes that KD and MAD can alter microbial composition, with changes in bacteria linked to ketone metabolism, GABAergic signaling, and inflammation. Non keto-focused approaches like LGIT and Mediterranean patterns may promote microbiome diversity and production of metabolites such as short-chain fatty acids, bile acids, and amino-acid derivatives that participate in MGBA signaling. Mechanistic pathways include altered microbial metabolite production (SCFAs, tryptophan metabolites), modulation of gut permeability and systemic endotoxemia, and immune cell cytokine profiles that may influence central nervous system excitability and neuroinflammation. The authors highlight that most evidence comes from small clinical trials and animal studies with heterogeneous designs, making causal inferences cautious. Correlations between microbial features and seizure outcomes exist but require replication. Overall, dietary therapies may exert MGBA-related effects through multiple, overlapping mechanisms, but more rigorous, controlled studies are needed to quantify their contribution to seizure control and therapy responsiveness.
Full Analysis
This review adopts a narrative synthesis to examine how dietary therapies may engage the MGBA to influence epilepsy biology. A key strength is its integration of data from diverse sources, including ketogenic and non-ketogenic diets, and both clinical and preclinical studies. Mechanistically, dietary interventions may alter gut microbiota composition, barrier integrity, and immune signaling, thereby modulating neuroinflammation and neuronal excitability through microbial metabolites such as SCFAs, bile acids, and tryptophan derivatives. The KD and MAD are highlighted for their potential to shift microbial communities toward taxa associated with ketone metabolism and anti-inflammatory mediators, potentially impacting GABAergic signaling and excitability. LGIT and Mediterranean-pattern diets may promote microbial diversity and metabolite profiles that support MGBA signaling. However, the evidence base is heterogeneous, with small sample sizes, diverse dietary formulations, and variable adherence, limiting causal inferences. Animal studies offer insights into plausible pathways but may not fully translate to humans. Human trials often rely on seizure outcomes, which can be confounded by antiepileptic drugs, comorbidities, and adherence. The review underscores the need for standardized dietary protocols, rigorous randomized controlled trials, and multi-omics approaches (microbiomics, metabolomics, immune profiling) to quantify MGBA contributions to seizure control. Future work should also consider individual microbiome baselines to tailor dietary strategies in epilepsy research, while maintaining nutritional adequacy and safety.Health Implications
Daily habits may support MGBA-related pathways without claiming seizure control. Consider a diverse, fiber-rich diet (fruits, vegetables, legumes, whole grains) to foster SCFA-producing microbes, along with regular intake of fermented foods (yogurt, kefir, sauerkraut) and polyphenol-rich items (berries, tea, olive oil). Hydration and consistent meal timing may help gut stability. If considering major dietary changes, consult a clinician or dietitian, especially for epilepsy patients on multiple medications or with nutritional risks. These practices may support gut health and inflammatory balance, which could interact with MGBA signaling and overall well-being.
Key Findings
- Dietary therapies may modulate gut microbiota composition, intestinal barrier function, and immune signaling, which could influence neuroinflammation and neuronal excitability via the MGBA.
- Ketogenic and non-ketogenic dietary approaches discussed may influence MGBA through multiple mechanisms, including metabolite production and gut-brain signaling.
DOI: 10.3390/nu18132151